Payment overview · 2025
General Payments
$302.98
17 reported records · 9 companies
Healthcare provider profile · identity verified
Kyle Travis Jones, DO
Allopathic & Osteopathic Physicians|Family Medicine · TULSA, OK · NPI 1164603262
Verified facts
What the public records show
CMS Open Payments records show Kyle Travis Jones, DO received $302.98 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $105.79 | 34.9% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.09 | 12.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.12 | 11.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.96 | 10.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.33 | 9.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.62 | 7.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.17 | 5.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.22 | 4.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $13.68 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $302.98 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.96 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.96 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.33 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 115 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
108 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
115 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 720 | 225 |
| Losartan Potassium | Losartan Potassium | 431 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 122 |
| Lisinopril | Lisinopril | 302 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 290 | 87 |
| Gabapentin | Gabapentin | 243 | 67 |
| Omeprazole | Omeprazole | 232 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 195 | 75 |
| Tramadol Hcl | Tramadol Hcl | 191 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 57 |
| Trazodone Hcl | Trazodone Hcl | 173 | 63 |
| Metformin Hcl Er | Metformin Hcl | 157 | 52 |
| Potassium Chloride | Potassium Chloride | 148 | 38 |
| Eliquis | Apixaban | 141 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 42 |
| Ozempic | Semaglutide | 140 | 27 |
| Furosemide | Furosemide | 139 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 42 |
| Carvedilol | Carvedilol | 130 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 28 |
| Mounjaro | Tirzepatide | 115 | 19 |
| Prednisone | Prednisone | 115 | 63 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 57 |
| Farxiga | Dapagliflozin Propanediol | 108 | 19 |
| Alendronate Sodium | Alendronate Sodium | 100 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 25 |
| Jardiance | Empagliflozin | 83 | 20 |
| Metformin Hcl | Metformin Hcl | 83 | 26 |
| Azithromycin | Azithromycin | 82 | 70 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 17 |
| Celecoxib | Celecoxib | 79 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 22 |
| Simvastatin | Simvastatin | 77 | 21 |
| Alprazolam | Alprazolam | 76 | 18 |
| Donepezil Hcl | Donepezil Hcl | 74 | 28 |
| Pregabalin | Pregabalin | 73 | 19 |
| Montelukast Sodium | Montelukast Sodium | 71 | 20 |
| Sertraline Hcl | Sertraline Hcl | 70 | 27 |
| Clonazepam | Clonazepam | 69 | 13 |
| Trulicity | Dulaglutide | 68 | 11 |
| Buspirone Hcl | Buspirone Hcl | 67 | 18 |
| Trospium Chloride | Trospium Chloride | 65 | 23 |
| Clonidine Hcl | Clonidine Hcl | 63 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 16 |
| Meloxicam | Meloxicam | 59 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 21 |
| Allopurinol | Allopurinol | 55 | 18 |
| Temazepam | Temazepam | 55 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 54 | 15 |
| Mirtazapine | Mirtazapine | 53 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 27 |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 15 |
| Spironolactone | Spironolactone | 43 | 17 |
| Famotidine | Famotidine | 42 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 22 |
| Fluconazole | Fluconazole | 39 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 23 |
| Testosterone | Testosterone | 39 | 13 |
| Torsemide | Torsemide | 39 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 33 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | 13 |
| Estradiol | Estradiol | 35 | 13 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 33 | 19 |
| Naproxen | Naproxen | 32 | 12 |
| Cephalexin | Cephalexin | 30 | 25 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | 11 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | 11 |
| Methylprednisolone | Methylprednisolone | 26 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | 11 |
| Valsartan | Valsartan | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 17 |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $302.98 · 17 records | AstraZeneca Pharmaceuticals LP | Cologuard Collection Kit, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, XIFAXAN, YUPELRI, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error